Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?

Idiopathic pulmonary fibrosis is a rare, progressive and fatal lung disease which affects approximately 5 million persons worldwide. Although pirfenidone and/or nintedanib treatment improves patients’ wellbeing, the prognosis of IPF remains poor with 5-year mortality rates still ranging from 70 to 8...

Descripción completa

Detalles Bibliográficos
Autores principales: Duitman, JanWillem, van den Ende, Tom, Spek, C. Arnold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6833050/
https://www.ncbi.nlm.nih.gov/pubmed/31561518
http://dx.doi.org/10.3390/jcm8101547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6833050/
https://www.ncbi.nlm.nih.gov/pubmed/31561518
http://dx.doi.org/10.3390/jcm8101547

Ejemplares similares